Group items matching

in title, tags, annotations or url

The Office of Naval Research (ONR), ONR Global, and Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWLs broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines.

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

Supports spinal cord injury research in three award categories: pilot for newly independent investigators, postdoctoral for early career researchers and senior for established investigators Who should apply: Spinal cord injury researchers

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) solicits research proposals to address significant challenges in Fetal Alcohol Spectrum Disorders (FASD) research in the areas of diagnosis/screening, etiology, interventions and treatment. Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects, based on new and innovative concepts, approaches, and technologies. This solicitation is open to all. To maximize the impact of their research, awardees will be encouraged to establish a collaborative relationship with the NIAAA-supported Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) consortium.

This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN) and contribute to the network's capacity to respond to urgent public health needs. NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, healthcare providers, and healthcare institutions.   

The purpose of this funding opportunity announcement (FOA) is to invite applications to participate as a Research Center in the Pediatric Cardiac Genomics Consortium (PCGC) (http://www.benchtobassinet.com/). The PCGCs mission is to identify genetic causes of human congenital heart disease (CHD) and to relate genetic variants in patients with CHD to clinical outcomes through collaborative, multi-center studies. The PCGC fosters investigation along the translational spectrum of CHD research through interactions with Cardiovascular Development Data Resource Center (CDDRC, previously the Cardiovascular Development Consortium) and the Pediatric Heart Network (PHN). Together, they constitute the Bench to Bassinet Program (http://www.benchtobassinet.com/ProgramOverview.asp) (B2B). Sites not currently part of the PCGC are encouraged to apply and propose new directions for the consortium.

A rare disease is defined by the Orphan Drug Act as a disease that affects less than 200,000 people in the US. As described in FDA draft Guidance, "Rare Diseases: Common Issues in Drug Development Guidance for Industry" (https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm458485.pdf ), fit-for-purpose clinical endpoints for many rare diseases are not available. Selection or development of clinical outcome assessments for use to support efficacy of a treatment in a rare disease can be challenging due to the small sample size of possible participants for participation in instrument development and clinical trials and heterogeneity of the target patient population (e.g., phenotypic or genotypic variations, age, clinical manifestations, variations in patient experience, and rate of disease progression). However, many rare diseases share similar clinical characteristics such as decline in cognition and physical function, which offers an opportunity to explore clinical outcome assessments that may cover a spectrum of rare diseases.

This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.

This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's Disease (AD) and AD Related Dementias (ADRD) in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson's disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson's disease or enhancing the well-being of individuals experiencing the impact of the disease.

The Simons Foundation Autism Research Initiative improves the understanding, diagnosis, and treatment of autism spectrum disorders by funding innovative research of the highest quality and relevance. To that end, SFARI is inviting applications for its SFARI Research Awards from individuals ready to conduct bold and rigorous research. The goal of the award is to provide support for investigation of key unresolved research questions in autism, particularly those that connect genetic etiologies to brain function and behavior. The program welcomes risk and novelty, but they are not required criteria for a proposal to be considered meritorious.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that would develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R21 grant mechanism, while RFA- MH-19-120 uses the R01 grant mechanism. Applications with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may be more appropriate for the R01 mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be more appropriate for this FOA (R21 mechanism).

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R01 grant mechanism, while RFA-MH-19-121 uses the R21 grant mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be most appropriate for the R21 mechanism. Applicants with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may wish to use this FOA (R01 mechanism).

The Autism Science Foundation is inviting applications for its Pre- and Postdoctoral Training Awards and Medical School Gap Year Research Training Awards from graduate students, medical students, and postdoctoral fellows interested in pursuing careers in basic and clinical research relevant to autism spectrum disorders. The proposed training must be scientifically linked to autism and may be broadened to include training in a closely related area of scientific research, including but not limited to human behavior across the lifespan (language, learning, behavior, communication, social function, motor skills and planning, epilepsy, sleep, repetitive disorders); neurobiology (anatomy, development, neuroimaging); pharmacology; neuropathology; genetics; epigenetics; genomics; epigenomics; immunology; molecular and cellular mechanisms; studies employing model organisms and systems; and studies of treatment and service delivery.

This Funding Opportunity Announcement (FOA) invites applications that propose to develop and implement early stage (Phase I or II) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to enhance trial design and methods.

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson's disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson's disease or enhancing the well-being of individuals experiencing the impact of the disease.

The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and pursue high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and to transform these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts that address one or more of the following technical domains:

The LRP Impact Award encourages applications that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through inferential reasoning and/or critical review and analysis of the literature. Inclusion of preliminary data is encouraged.

Through the program, grants of up to $100,000 over eighteen months will be awarded to projects that advance our understanding of the genetic basis of autism spectrum disorder. Data to be analyzed through the program will include whole-exome and genome-wide genotyping data from approximately forty-five hundred individuals with ASD enrolled in SPARK and their biological parents. Approximately half of these families will also have genomic data from an unaffected sibling. Whole-genome sequencing data from an additional four hundred ASD individuals, plus their biological parents and unaffected siblings, is also expected to be available. In addition, a limited phenotypic data set on all participants will be available.

Pharmaceutical company AmerisourceBergen created the AmerisourceBergen Foundation as a separate not-for-profit charitable organization with the aim of supporting health and education-related causes that enrich the lives of its global community. To accomplish that goal, the foundation provides funding for programs and organizations focused on expanding access to quality healthcare - both human and animal - around the world. In the view of the foundation, the current epidemic of opioid abuse and misuse is a crisis that demands attention, action, and accountability. Understanding the need for expediency, the foundation is inviting grant-funded nonprofit organizations to submit proposals that describe how it can best contribute resources and funding to address opioid abuse and misuse. Grants will be awarded for the most innovative and constructive solutions in one of two key areas of focus: safe disposal and education around prevention. Applicants are strongly encouraged to identify and leverage existing, proven, evidence-based frameworks and strategies, as well as existing tools and materials, but may also propose original and innovative projects. Applications focused on education may address a spectrum of needs, but priority will be given to the effective dissemination of the following topics: provider education about appropriate opioid prescribing; patient education about the risks and effects of prescription opioids, and what to do if they have concerns about addiction; public education, especially aimed at rural communities; training to reduce youth risk factors (such as delinquency) and boost protective factors (such as decision-making skills for problem solving and resisting peer pressure; addiction as a childhood onset condition; preventing teens from initiating problematic opioid use in the first place; and advising parents of teens to lock up prescription opioid medications and dispose of old pills.